![David Moss](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Moss
Geen lopende functies
Profiel
David Moss worked as a Research Director at Cambridge Biostability Ltd.
and as a Project Director at Xenetic Biosciences (UK) Ltd.
in 2009.
Eerdere bekende functies van David Moss
Bedrijven | Functie | Einde |
---|---|---|
Cambridge Biostability Ltd.
![]() Cambridge Biostability Ltd. Pharmaceuticals: MajorHealth Technology Cambridge Biostability Ltd. manufactures vaccines and drugs. The firm's two platforms VitRIS and HydRIS offers pharmaceuticals, vaccines, and other biological products in thermo-stable, instantly-injectable formats. The company was founded by Dr Bruce Roser in 2003 and is headquartered in UK. | Hoofd Techniek/Wetenschap/O&O | 16-06-2010 |
Xenetic Biosciences (UK) Ltd.
![]() Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Cambridge Biostability Ltd.
![]() Cambridge Biostability Ltd. Pharmaceuticals: MajorHealth Technology Cambridge Biostability Ltd. manufactures vaccines and drugs. The firm's two platforms VitRIS and HydRIS offers pharmaceuticals, vaccines, and other biological products in thermo-stable, instantly-injectable formats. The company was founded by Dr Bruce Roser in 2003 and is headquartered in UK. | Health Technology |
Xenetic Biosciences (UK) Ltd.
![]() Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | Health Technology |